Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump ...

Since being approved, Wegovy's popularity has soared, to the point where the drug has made its maker, Novo Nordisk -- for ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection ...

Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus ahead of a major drug pricing deal with the Trump ...

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

Historical trends show that even leading firms can experience abrupt market fluctuations, where stocks can plummet ...

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio. Lilly stock popped ...